United States Biotechnology & Medical Research

Geron Corp (GERN)

Track

There has been no insider trading activity at Geron Corp in the last three months. The most recent transaction occurred on February 18, 2026, when the EVP and Chief Financial Officer executed a sale of shares. Prior to this, activity included a mix of proposed sales and open market purchases by various executives.
Ticker: GERN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Geron Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
ROBERTSON MICHELLE
EVP, CHIEF FINANCIAL OFFICER
1 sale — total 19,119 USD
Sale 18 Feb 2026
Value US$1,889,237.91 | Price 294.90 | Shares 12,502
Proposed sale 15 Dec 2025
Value US$395,013.53 | Price 127.51 | Shares 41,867
Buy 9 May 2025
Value US$15,667.40 | Price 1.18 | Shares 13,300
Buy 27 Feb 2025
Value US$22,062.50 | Price 1.77 | Shares 12,500
Buy 27 Feb 2025
Value US$160,000.00 | Price 1.60 | Shares 100,000
Buy 27 Feb 2025
Value US$24,150.00 | Price 1.61 | Shares 15,000
Sale 8 Jul 2024
Value US$3,073,003.84 | Price 4.56 | Shares 674,348
Proposed sale 8 Jul 2024
Value US$2,933,413.80 | Price 4.35 | Shares 674,348
Sale 10 Jun 2024
Value US$1,959,609.38 | Price 4.65 | Shares 421,875
Proposed sale 10 Jun 2024
Value US$1,961,941.08 | Price 4.65 | Shares 421,875
Sale 10 Jun 2024
Value US$1,334,128.60 | Price 4.63 | Shares 287,900
Proposed sale 10 Jun 2024
Value US$1,337,989.63 | Price 4.65 | Shares 287,900
Planned sale 4 Jun 2024
Value US$2,400,000.00 | Price 4.00 | Shares 600,000
Proposed sale 4 Jun 2024
Value US$2,400,000.00 | Price 4.00 | Shares 600,000
Planned sale 15 May 2024
Value US$131,250.00 | Price 3.75 | Shares 35,000
Proposed sale 15 May 2024
Value US$131,274.50 | Price 3.75 | Shares 35,000
Buy 24 Aug 2023
Value US$15,000.12 | Price 2.28 | Shares 6,579
Buy 24 Aug 2023
Value US$15,063.96 | Price 2.28 | Shares 6,607
Proposed sale 11 May 2023
Value US$105,000.00 | Price 3.00 | Shares 35,000
Planned sale 11 May 2023
Value US$105,000.00 | Price 3.00 | Shares 35,000
Proposed sale 1 May 2023
Value US$86,653.00 | Price 2.48 | Shares 35,000
Planned sale 1 May 2023
Value US$86,800.00 | Price 2.48 | Shares 35,000
Planned sale 10 Feb 2023
Value US$1,340,004.00 | Price 3.00 | Shares 446,668
Planned sale 9 Feb 2023
Value US$711,198.57 | Price 3.03 | Shares 234,719
Planned sale 9 Feb 2023
Value US$454,500.00 | Price 3.03 | Shares 150,000
Planned sale 9 Feb 2023
Value US$1,353,397.98 | Price 3.03 | Shares 446,666
Planned sale 8 Feb 2023
Value US$1,232,000.00 | Price 3.08 | Shares 400,000
Planned sale 8 Feb 2023
Value US$1,375,731.28 | Price 3.08 | Shares 446,666
Buy 21 Aug 2020
Value US$30,172.93 | Price 1.73 | Shares 17,441
Buy 10 Jan 2020
Value US$2,948.00 | Price 1.34 | Shares 2,200
Buy 10 Jan 2020
Value US$1,080.00 | Price 1.35 | Shares 800
Planned sale 9 Apr 2019
Value US$241,270.00 | Price 2.00 | Shares 120,635
Planned sale 13 Sep 2018
Value US$239,750.00 | Price 6.85 | Shares 35,000
Planned sale 13 Sep 2018
Value US$239,750.00 | Price 6.85 | Shares 35,000
Planned sale 13 Sep 2018
Value US$239,750.00 | Price 6.85 | Shares 35,000
Planned sale 13 Sep 2018
Value US$102,750.00 | Price 6.85 | Shares 15,000
Planned sale 13 Sep 2018
Value US$68,500.00 | Price 6.85 | Shares 10,000
Planned sale 13 Sep 2018
Value US$308,250.00 | Price 6.85 | Shares 45,000
Planned sale 24 Aug 2018
Value US$169,125.00 | Price 4.51 | Shares 37,500
Planned sale 24 Aug 2018
Value US$507,375.00 | Price 4.51 | Shares 112,500
Planned sale 24 Aug 2018
Value US$591,937.50 | Price 4.51 | Shares 131,250
Planned sale 24 Aug 2018
Value US$1,894,200.00 | Price 4.51 | Shares 420,000
Planned sale 24 Aug 2018
Value US$902,000.00 | Price 4.51 | Shares 200,000
Planned sale 24 Aug 2018
Value US$1,916,750.00 | Price 4.51 | Shares 425,000
Planned sale 24 Aug 2018
Value US$162,360.00 | Price 4.51 | Shares 36,000
Sale 18 Mar 2015
Value US$287,000.00 | Price 4.10 | Shares 70,000
Buy 9 May 2014
Value US$249,858.00 | Price 1.75 | Shares 142,776
Buy 1 Apr 2013
Value US$51,500.00 | Price 1.03 | Shares 50,000
Sale 17 Jan 2013
Value US$46,568.63 | Price 1.65 | Shares 28,292
Buy 22 Nov 2011
Value US$100,269.00 | Price 1.56 | Shares 64,275
Buy 5 Oct 2011
Value US$101,500.00 | Price 2.03 | Shares 50,000
Sale 2 Feb 2009
Value US$119,891.80 | Price 8.12 | Shares 14,765
Sale 30 Jan 2009
Value US$402,548.76 | Price 8.28 | Shares 48,617
Sale 29 Jan 2009
Value US$177,000.00 | Price 7.08 | Shares 25,000
Sale 29 Jan 2009
Value US$39,191.46 | Price 7.14 | Shares 5,489
Sale 5 Nov 2008
Value US$96,572.25 | Price 4.05 | Shares 23,845
Sale 4 Jan 2008
Value US$47,584.74 | Price 5.34 | Shares 8,911
Sale 4 Jan 2008
Value US$47,584.74 | Price 5.34 | Shares 8,911
Sale 4 Jan 2008
Value US$47,584.74 | Price 5.34 | Shares 8,911
Sale 4 Jan 2008
Value US$58,948.26 | Price 5.34 | Shares 11,039
Sale 4 Jan 2008
Value US$47,584.74 | Price 5.34 | Shares 8,911
Sale 4 Jan 2008
Value US$70,306.44 | Price 5.34 | Shares 13,166
Sale 12 Nov 2007
Value US$28,800.00 | Price 7.20 | Shares 4,000
Sale 18 May 2007
Value US$27,390.00 | Price 9.13 | Shares 3,000
Sale 18 May 2007
Value US$82,350.00 | Price 9.15 | Shares 9,000
Sale 18 May 2007
Value US$82,890.00 | Price 9.21 | Shares 9,000
Sale 18 May 2007
Value US$82,980.00 | Price 9.22 | Shares 9,000
Sale 9 Jan 2006
Value US$104,286.48 | Price 8.56 | Shares 12,183
Sale 9 Jan 2006
Value US$91,386.56 | Price 8.56 | Shares 10,676
Sale 9 Jan 2006
Value US$96,924.88 | Price 8.56 | Shares 11,323
Sale 9 Jan 2006
Value US$78,606.48 | Price 8.56 | Shares 9,183
Sale 9 Jan 2006
Value US$72,254.96 | Price 8.56 | Shares 8,441
Sale 9 Jan 2006
Value US$105,459.20 | Price 8.56 | Shares 12,320
Sale 29 Jul 2005
Value US$212,508.16 | Price 10.88 | Shares 19,532
Sale 29 Jul 2005
Value US$500,904.32 | Price 10.88 | Shares 46,039
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-19 2026-02-18 S Sale
4.1
ROBERTSON MICHELLE

EVP, CHIEF FINANCIAL OFFICER

Officer
12,502 -47.9%
294.90
US$1,889,238 		12,502 -47.9% 294.90 US$1,889,238
2025-12-15 2025-12-15 PrS Proposed sale
1.0
JAMES ZIEGLER

Officer

Officer
41,867
127.51
US$395,014 		41,867 127.51 US$395,014
2025-05-13 2025-05-09 B Purchase
3.1
LAWLIS V BRYAN
Non-Executive Director
23,533 +34.5%
242.44
US$2,231,583 		23,533 +34.5% 242.44 US$2,231,583
2025-03-03 2025-02-27 B Purchase
0.7
SCARLETT JOHN A

Chairman, President and CEO

Executive Director
12,500 +inf%
1.77
US$22,062 		12,500 +inf% 1.77 US$22,062
2025-03-03 2025-02-27 B Purchase
1.0
Ziegler James

EVP, Chief Commercial Officer

Officer
100,000 +inf%
1.60
US$160,000 		100,000 +inf% 1.60 US$160,000
2025-03-03 2025-02-27 B Purchase
1.0
Samuels Scott Alan

EVP, Chief Legal Officer

Officer
15,000 +128.4%
1.61
US$24,150 		15,000 +128.4% 1.61 US$24,150
2024-07-10 2024-07-08 S Sale
2.3
GRETHLEIN ANDREW J

EVP, Chief Operating Officer

Officer
674,348 -100.0%
4.56
US$3,073,004 		674,348 -100.0% 4.56 US$3,073,004
2024-07-08 2024-07-08 PrS Proposed sale
2.3
GRETHLEIN ANDREW J

Officer

Officer
674,348
4.35
US$2,933,414 		674,348 4.35 US$2,933,414
2024-06-12 2024-06-10 S Sale
2.7
Kapur Anil

EVP, Corp Strategy & CCO

Officer
421,875 -100.0%
4.65
US$1,959,609 		421,875 -100.0% 4.65 US$1,959,609
2024-06-12 2024-06-10 S Sale
2.7
Feller Faye

EVP, Chief Medical Officer

Officer
287,900 -100.0%
4.63
US$1,334,129 		287,900 -100.0% 4.63 US$1,334,129
2024-06-10 2024-06-10 PrS Proposed sale
2.7
Feller Faye

Officer

Officer
287,900
4.65
US$1,337,990 		287,900 4.65 US$1,337,990
2024-06-10 2024-06-10 PrS Proposed sale
2.7
Kapur Anil

Officer

Officer
421,875
4.65
US$1,961,941 		421,875 4.65 US$1,961,941
2024-06-05 2024-06-04 PlS Planned sale
0.7
SCARLETT JOHN A

Chairman, President and CEO

Executive Director
600,000 -50.0%
4.00
US$2,400,000 		600,000 -50.0% 4.00 US$2,400,000
2024-06-04 2024-06-04 PrS Proposed sale
0.7
JOHN A SCARLETT

Officer; Director

Executive Director
600,000
4.00
US$2,400,000 		600,000 4.00 US$2,400,000
2024-05-17 2024-05-15 PlS Planned sale
3.1
LAWLIS V BRYAN
Non-Executive Director
35,000 -100.0%
3.75
US$131,250 		35,000 -100.0% 3.75 US$131,250
2024-05-15 2024-05-15 PrS Proposed sale
3.1
BRYAN LAWLIS JR.

Director

Non-Executive Director
35,000
3.75
US$131,274 		35,000 3.75 US$131,274
2023-08-24 2023-08-24 B Purchase
2.6
O'Farrell Elizabeth G.
Non-Executive Director
6,579 +33.5%
2.28
US$15,000 		6,579 +33.5% 2.28 US$15,000
2023-08-24 2023-08-24 B Purchase
2.6
O'Farrell Elizabeth G.
Non-Executive Director
6,607 +825.9%
2.28
US$15,064 		6,607 +825.9% 2.28 US$15,064
2023-05-11 2023-05-11 PrS Proposed sale
3.1
BRYAN LAWLIS JR

Director

Non-Executive Director
35,000
3.00
US$105,000 		35,000 3.00 US$105,000
2023-05-11 2023-05-11 PlS Planned sale
3.1
LAWLIS V BRYAN
Non-Executive Director
35,000 -100.0%
3.00
US$105,000 		35,000 -100.0% 3.00 US$105,000
2023-05-01 2023-05-01 PrS Proposed sale
SUSAN MOLINEAUX

Director

Non-Executive Director
35,000
2.48
US$86,653 		35,000 2.48 US$86,653
2023-05-01 2023-05-01 PlS Planned sale
Molineaux Susan
Non-Executive Director
35,000 -100.0%
2.48
US$86,800 		35,000 -100.0% 2.48 US$86,800
2023-02-10 2023-02-10 PlS Planned sale
0.7
SCARLETT JOHN A

Chairman, President and CEO

Executive Director
446,668 -100.0%
3.00
US$1,340,004 		446,668 -100.0% 3.00 US$1,340,004
2023-02-10 2023-02-09 PlS Planned sale
2.3
GRETHLEIN ANDREW J

EVP, Chief Operating Officer

Officer
234,719 -100.0%
3.03
US$711,199 		234,719 -100.0% 3.03 US$711,199
2023-02-10 2023-02-09 PlS Planned sale
2.3
GRETHLEIN ANDREW J

EVP, Chief Operating Officer

Officer
150,000 -39.0%
3.03
US$454,500 		150,000 -39.0% 3.03 US$454,500
2023-02-10 2023-02-09 PlS Planned sale
0.7
SCARLETT JOHN A

Chairman, President and CEO

Executive Director
446,666 -100.0%
3.03
US$1,353,398 		446,666 -100.0% 3.03 US$1,353,398
2023-02-10 2023-02-08 PlS Planned sale
Bloom Olivia Kyusuk

EVP, Chief Financial Officer

Officer
400,000 -84.3%
3.08
US$1,232,000 		400,000 -84.3% 3.08 US$1,232,000
2023-02-10 2023-02-08 PlS Planned sale
0.7
SCARLETT JOHN A

Chairman, President and CEO

Executive Director
446,666 -100.0%
3.08
US$1,375,731 		446,666 -100.0% 3.08 US$1,375,731
2020-08-24 2020-08-21 B Purchase
2.6
O'Farrell Elizabeth G.
Non-Executive Director
17,441 +792.8%
1.73
US$30,173 		17,441 +792.8% 1.73 US$30,173
2020-01-13 2020-01-10 B Purchase
2.6
O'Farrell Elizabeth G.
2,200 +inf%
1.34
US$2,948 		2,200 +inf% 1.34 US$2,948
2020-01-13 2020-01-10 B Purchase
2.6
O'Farrell Elizabeth G.
800 +inf%
1.35
US$1,080 		800 +inf% 1.35 US$1,080
2019-04-10 2019-04-09 PlS Planned sale
BEHRS MELISSA KELLY

EVP, Chief Business Officer
120,635 -100.0%
2.00
US$241,270 		120,635 -100.0% 2.00 US$241,270
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
35,000 -34.8%
6.85
US$239,750 		35,000 -34.8% 6.85 US$239,750
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
35,000 -34.8%
6.85
US$239,750 		35,000 -34.8% 6.85 US$239,750
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
35,000 -34.8%
6.85
US$239,750 		35,000 -34.8% 6.85 US$239,750
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
15,000 -18.6%
6.85
US$102,750 		15,000 -18.6% 6.85 US$102,750
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
10,000 -13.2%
6.85
US$68,500 		10,000 -13.2% 6.85 US$68,500
2018-09-13 2018-09-13 PlS Planned sale Spiegel Robert J. Non-Executive Director
45,000 -40.7%
6.85
US$308,250 		45,000 -40.7% 6.85 US$308,250
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
37,500 -100.0%
4.51
US$169,125 		37,500 -100.0% 4.51 US$169,125
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
112,500 -100.0%
4.51
US$507,375 		112,500 -100.0% 4.51 US$507,375
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
131,250 -100.0%
4.51
US$591,938 		131,250 -100.0% 4.51 US$591,938
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
420,000 -100.0%
4.51
US$1,894,200 		420,000 -100.0% 4.51 US$1,894,200
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
200,000 -100.0%
4.51
US$902,000 		200,000 -100.0% 4.51 US$902,000
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
425,000 -100.0%
4.51
US$1,916,750 		425,000 -100.0% 4.51 US$1,916,750
2018-08-24 2018-08-24 PlS Planned sale ROSENFIELD STEPHEN

EVP, Genl Counsel & Secretary

Officer
36,000 -100.0%
4.51
US$162,360 		36,000 -100.0% 4.51 US$162,360
2015-03-19 2015-03-18 S Sale Hofstaetter Thomas Non-Executive Director
70,000 -72.5%
4.10
US$287,000 		70,000 -72.5% 4.10 US$287,000
2014-05-12 2014-05-09 B Purchase BRADBURY DANIEL Non-Executive Director
142,776 +inf%
1.75
US$249,858 		142,776 +inf% 1.75 US$249,858
2013-04-01 2013-04-01 B Purchase SCARLETT JOHN A

President and CEO

Executive Director
50,000 +66.7%
1.03
US$51,500 		50,000 +66.7% 1.03 US$51,500
2013-01-22 2013-01-17 S Sale BEHRS MELISSA KELLY

SVP Alliance and Prog Mgmt

Officer
28,292 -100.0%
1.65
US$46,569 		28,292 -100.0% 1.65 US$46,569
2011-11-23 2011-11-22 B Purchase KILEY THOMAS Non-Executive Director
64,275 +25.7%
1.56
US$100,269 		64,275 +25.7% 1.56 US$100,269
2011-10-06 2011-10-05 B Purchase KILEY THOMAS Non-Executive Director
50,000 +107.2%
2.03
US$101,500 		50,000 +107.2% 2.03 US$101,500
2009-02-03 2009-02-02 S Sale BEHRS MELISSA KELLY

SVP Oncology

Officer
14,765 -100.0%
8.12
US$119,892 		14,765 -100.0% 8.12 US$119,892
2009-01-30 2009-01-30 S Sale WALKER JOHN PETER Non-Executive Director
48,617 -55.4%
8.28
US$402,549 		48,617 -55.4% 8.28 US$402,549
2009-01-30 2009-01-29 S Sale HARLEY CALVIN

VP and CSO

Officer
25,000 -20.1%
7.08
US$177,000 		25,000 -20.1% 7.08 US$177,000
2009-01-30 2009-01-29 S Sale HARLEY CALVIN

VP and CSO

Officer
5,489 -4.2%
7.14
US$39,191 		5,489 -4.2% 7.14 US$39,191
2008-11-05 2008-11-05 S Sale BEHRS MELISSA KELLY

SVP Oncology

Officer
23,845 -21.2%
4.05
US$96,572 		23,845 -21.2% 4.05 US$96,572
2008-01-04 2008-01-04 S Sale EARP DAVID

SVP Bus Dev, Chief Patnt Couns

Officer
8,911 -5.4%
5.34
US$47,585 		8,911 -5.4% 5.34 US$47,585
2008-01-04 2008-01-04 S Sale BEHRS MELISSA KELLY

SVP Oncology

Officer
8,911 -8.6%
5.34
US$47,585 		8,911 -8.6% 5.34 US$47,585
2008-01-04 2008-01-04 S Sale LEBKOWSKI JANE

SVP Regen Medicine

Officer
8,911 -5.7%
5.34
US$47,585 		8,911 -5.7% 5.34 US$47,585
2008-01-04 2008-01-04 S Sale GREENWOOD DAVID

EVP and CFO

Officer
11,039 -6.0%
5.34
US$58,948 		11,039 -6.0% 5.34 US$58,948
2008-01-04 2008-01-04 S Sale HARLEY CALVIN

VP and CSO

Officer
8,911 -6.9%
5.34
US$47,585 		8,911 -6.9% 5.34 US$47,585
2008-01-04 2008-01-04 S Sale OKARMA THOMAS

President and CEO

Officer
13,166 -3.5%
5.34
US$70,306 		13,166 -3.5% 5.34 US$70,306
2007-11-13 2007-11-12 S Sale GREENWOOD DAVID

EVP and CFO

Officer
4,000 -2.2%
7.20
US$28,800 		4,000 -2.2% 7.20 US$28,800
2007-05-21 2007-05-18 S Sale HARLEY CALVIN

VP and CSO

Officer
3,000 -5.0%
9.13
US$27,390 		3,000 -5.0% 9.13 US$27,390
2007-05-21 2007-05-18 S Sale HARLEY CALVIN

VP and CSO

Officer
9,000 -13.0%
9.15
US$82,350 		9,000 -13.0% 9.15 US$82,350
2007-05-21 2007-05-18 S Sale HARLEY CALVIN

VP and CSO

Officer
9,000 -11.5%
9.21
US$82,890 		9,000 -11.5% 9.21 US$82,890
2007-05-21 2007-05-18 S Sale HARLEY CALVIN

VP and CSO

Officer
9,000 -10.3%
9.22
US$82,980 		9,000 -10.3% 9.22 US$82,980
2006-01-10 2006-01-09 S Sale GREENWOOD DAVID

Executive VP and CFO

Officer
12,183 -41.8%
8.56
US$104,286 		12,183 -41.8% 8.56 US$104,286
2006-01-10 2006-01-09 S Sale LEBKOWSKI JANE

SVP, Regenerative Medicine

Officer
10,676 -35.7%
8.56
US$91,387 		10,676 -35.7% 8.56 US$91,387
2006-01-10 2006-01-09 S Sale EARP DAVID

SVP Bus Dev / Chf Patent Couns

Officer
11,323 -35.7%
8.56
US$96,925 		11,323 -35.7% 8.56 US$96,925
2006-01-10 2006-01-09 S Sale HARLEY CALVIN

Chief Scientific Officer

Officer
9,183 -53.3%
8.56
US$78,606 		9,183 -53.3% 8.56 US$78,606
2006-01-10 2006-01-09 S Sale BEHRS MELISSA KELLY

VP, Oncology

Officer
8,441 -53.4%
8.56
US$72,255 		8,441 -53.4% 8.56 US$72,255
2006-01-10 2006-01-09 S Sale OKARMA THOMAS

President and CEO

Executive Director
12,320 -28.1%
8.56
US$105,459 		12,320 -28.1% 8.56 US$105,459
2005-08-01 2005-07-29 S Sale KELLY MELISSA

VP, Oncology

Officer
19,532 -77.4%
10.88
US$212,508 		19,532 -77.4% 10.88 US$212,508
2005-08-01 2005-07-29 S Sale KELLY MELISSA

VP, Oncology

Officer
46,039 -64.6%
10.88
US$500,904 		46,039 -64.6% 10.88 US$500,904
Explore more

More insider trading research around Geron Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America